Who Paid My Doc
Elias Sobrino Najul
Hematology & Oncology Bayamon, PR Medical Doctor
NPI 1598182719 CMS profile 4216923
Torre San Pablo Suite 503, 68 Calle Santa Cruz, Bayamon, PR 00961
General payments
$17,451
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$305,393
Through program year 2025, Elias Sobrino Najul of Bayamon, PR is reported in the CMS Open Payments database as having received $17,451 across 512 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $305,393 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 79th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,722 | 120 | |
| 2024 | General | $4,001 | 69 | |
| 2023 | General | $5,047 | 83 | |
| 2022 | General | $2,278 | 99 | |
| 2021 | General | $2,178 | 91 | |
| 2020 | General | $754 | 31 | |
| 2019 | General | $470 | 19 |
Beside peers
- Elias Sobrino Najul
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Elias Sobrino Najul were reported at $2,722. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Elias Sobrino Najul | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $470 | $529 | $121–$2,516 | $163 |
| 2020 | $754 | $339 | $82–$2,213 | $114 |
| 2021 | $2,178 | $263 | $49–$1,965 | $132 |
| 2022 | $2,278 | $416 | $103–$2,395 | $149 |
| 2023 | $5,047 | $542 | $125–$2,646 | $160 |
| 2024 | $4,001 | $692 | $141–$3,008 | $164 |
| 2025 | $2,722 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 30 drugsPart D claims
776
Drug cost
$3,488,066
Branded share of claims
36%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xtandi Enzalutamide | Brand | 57 | $813,073 | |
| Orserdu Elacestrant Hcl | Brand | 24 | $557,036 | |
| Ibrance Palbociclib | Brand | 26 | $408,890 | |
| Tagrisso Osimertinib Mesylate | Brand | 17 | $262,485 | |
| Venclexta Venetoclax | Brand | 17 | $241,182 | |
| Erleada Apalutamide | Brand | 15 | $222,086 | |
| Nubeqa Darolutamide | Brand | 16 | $221,562 | |
| Imbruvica Ibrutinib | Brand | 12 | $211,367 | |
| Brukinsa Zanubrutinib | Brand | 13 | $200,948 | |
| Stivarga Regorafenib | Brand | 11 | $184,410 |
The 10 drugs with the highest cost, of 30 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 44 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| IMBRUVICA |
|
$1,925 | 12 | — |
| Pedmark |
|
$326 | — | — |
| TAGRISSO |
|
$144 | 17 | — |
| DARZALEX |
|
$137 | — | — |
| KEYTRUDA |
|
$131 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See more in the dashboard: 25 with a free account, all 44 with PatronRecords
512 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Puerto Rico
Alexis Cruz Chacon
Hematology & Oncology · San Juan, PR
Jose Lozada Costas
Hematology & Oncology · San Juan, PR
Cristian Rodriguez Arocho
Hematology & Oncology · San Juan, PR
Noridza Rivera Rodriguez
Hematology & Oncology · San Juan, PR
Joel Lopez-Figueroa
Hematology & Oncology · Humacao, PR
Mirelis Acosta
Hematology & Oncology · San Juan, PR
Related records
Hematology & Oncology in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.